MoonLake Immunotherapeutics Files 8-K
Ticker: MLTX · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1821586
| Field | Detail |
|---|---|
| Company | Moonlake Immunotherapeutics (MLTX) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, reporting
TL;DR
MoonLake filed an 8-K, mostly procedural stuff, no major news yet.
AI Summary
On September 29, 2025, MoonLake Immunotherapeutics filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. MoonLake Immunotherapeutics was formerly known as Helix Acquisition Corp until August 18, 2020.
Why It Matters
This 8-K filing indicates ongoing reporting requirements for MoonLake Immunotherapeutics, though the specific details of the 'Other Events' are not elaborated in this excerpt.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without disclosure of significant new material events or risks.
Key Players & Entities
- MoonLake Immunotherapeutics (company) — Registrant
- Helix Acquisition Corp (company) — Former Company Name
- September 29, 2025 (date) — Date of Report
- August 18, 2020 (date) — Date of Name Change
FAQ
What is the primary purpose of this 8-K filing?
The filing is a Current Report on Form 8-K, reporting 'Other Events' and 'Financial Statements and Exhibits' as of September 29, 2025.
When was MoonLake Immunotherapeutics formerly known as Helix Acquisition Corp?
MoonLake Immunotherapeutics was formerly known as Helix Acquisition Corp until August 18, 2020.
What is the principal executive office address for MoonLake Immunotherapeutics?
The address of the Principal Executive Offices is Dorfstrasse 29, 6300 Zug, Switzerland.
What is the Commission File Number for MoonLake Immunotherapeutics?
The Commission File Number for MoonLake Immunotherapeutics is 001-39630.
What is the SIC code for MoonLake Immunotherapeutics?
The Standard Industrial Classification (SIC) code for MoonLake Immunotherapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-09-29 07:15:53
Key Financial Figures
- $0.0001 — red Class A ordinary share, par value $0.0001 per share MLTX The Nasdaq Capital M
Filing Documents
- ea0259129-8k_moonlake.htm (8-K) — 25KB
- ea025912901ex99-1_moonlake.htm (EX-99.1) — 124KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001213900-25-092614.txt ( ) — 345KB
- mltx-20250929.xsd (EX-101.SCH) — 3KB
- mltx-20250929_lab.xml (EX-101.LAB) — 33KB
- mltx-20250929_pre.xml (EX-101.PRE) — 22KB
- ea0259129-8k_moonlake_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On September 28, 2025, MoonLake Immunotherapeutics (the "Company") issued a press release announcing the week 16 results of the Phase 3 VELA-1 and VELA-2 trials of its registrational global program in patients with moderate-to-severe hidradenitis suppurativa. The Company will host a webcast today, Monday, September 29, 2025 at 8:00 am, Eastern Time, to discuss the data results. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01. Financial
Item 9.01. Financial (d) Exhibits . The following exhibit is being filed herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated September 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOONLAKE IMMUNOTHERAPEUTICS Date: September 29, 2025 By: /s/ Matthias Bodenstedt Name: Matthias Bodenstedt Title: Chief Financial Officer 2